Skip to main content
. 2016 Oct 14;9(5):458–465. doi: 10.1016/j.tranon.2016.08.011

Figure 6.

Figure 6

Antitumor activity of PF-05212384, crizotinib or the combination in SKOV3 xenografts. A. Tumor growth inhibition activity of SKOV3 xenografts, treated with PF-05212384 10 mg/kg iv Q4dx4 (green arrows), crizotinib 50 mg/kg po every day (red line) or with the combination of the two drugs for 13 days. B. Percentage of tumor growth inhibition (T/C%) calculated for all the treatment groups. C. Body weight of SKOV3 bearing mice treated with PF-05212384, crizotinib or the combination. Means and SEM are shown. Statistical analysis was performed using two-way ANOVA test and Bonferroni post-test for multiple comparisons and no differences were detected.